ORIC Pharmaceuticals logo
ORIC Pharmaceuticals
ORIC | NASDAQ
Chart Builder DCF Calculator
$7.52
-$0.34 (-4.33%)
At close: Nov 16, 2026, 4:00 PM ET
$7.53
+$0.01 (+0.13%)
After-hours: Nov 16, 2026, 6:42 PM ET

ORIC Pharmaceuticals Company Profile

Company profile explained

Company Profile

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Key Executives

Name Position
Jacob Chacko President, Chief Executive Officer & Director
Dominic G. Piscitelli Chief Financial Officer
Charles L. Sawyers Founder & Member of Scientific Advisory Board
Christian V. Kuhlen General Counsel
Daniel Iazzetti Vice President & Head of People
Edna Chow Maneval Executive Vice President of Clinical Development
Kevin Brodbeck Chief Technical Officer
Lori Sickels Friedman Chief Scientific Officer
Pratik S. Multani Chief Medical Officer
Richard A. Heyman Founder, Independent Chairman & Member of Scientific Advisory Board
Scott W. Lowe Founder & Member of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Oct 23, 2026 8-K Current Report
Oct 21, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 29, 2026 4 Filing
Sep 25, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 26, 2026 144 Filing
Aug 03, 2026 10-Q Quarterly Report
Aug 03, 2026 8-K Current Report
Jul 30, 2026 S-8 Filing
View All SEC Filings ➞
ORIC Pharmaceuticals
ORIC Pharmaceuticals logo
Country United States
IPO Date Apr 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 111
CEO Jacob Chacko

Contact Details

240 East Grand Avenue South San Francisco, California 94080 United States

Stock Details

Ticker Symbol ORIC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001796280
CUSIP Number 68622P109
ISIN Number US68622P1093
SIC Code 2834

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.